EurekaMag.com logo
+ Site Statistics
References:
53,869,633
Abstracts:
29,686,251
+ Search Articles
+ Subscribe to Site Feeds
EurekaMag Most Shared ContentMost Shared
EurekaMag PDF Full Text ContentPDF Full Text
+ PDF Full Text
Request PDF Full TextRequest PDF Full Text
+ Follow Us
Follow on FacebookFollow on Facebook
Follow on TwitterFollow on Twitter
Follow on LinkedInFollow on LinkedIn

+ Translate

Iron chelating, antioxidant and cytoprotective properties of dopamine receptor agonist; apomorphine



Iron chelating, antioxidant and cytoprotective properties of dopamine receptor agonist; apomorphine



Journal of Neural Transmission. Supplementum: 83-96



There have been many attempts to discover neuroprotective drugs for the treatment of Parkinson's disease (PD). Many of these compounds either do not cross the blood brain barrier or are not very effective in the 6-hydroxydopamine or MPTP (N-methyl-4-pheny1-1,2,3,6-terahydropyridine) models of PD. We have examined several compounds including dopamine receptor agonist bromocritine, lisuride, pergolide and R-apomorphine for their neuroprotective action against the above neurotoxins in PC12 and dopamine neuroblastoma cell lines in culture and in vivo. R-apomorphine exhibited relatively potent neuroprotective action in vitro, cell culture and in vivo as a radical scavenger and iron chelator, because of its catechol structure. The recent clinical trials with apomorphine, where parkinsonian subjects can be weaned off L-dopa would suggest that this drug either exerts a neuroprotective action or that continuous sustained stimulation of dopamine receptor may be responsible for its unusual pharmacological activity. Apomorphine has a far more broad neuroprotective activity in the various models as compared with l-selegiline and may therefore be an ideal drug to study neuroprotection in parkinsonian subjects with the use of PET or SPECT.

(PDF emailed within 1 workday: $29.90)

Accession: 010885078

Download citation: RISBibTeXText

PMID: 11128615



Related references

Apomorphine, a dopamine receptor agonist with remarkable antioxidant and cytoprotective properties. Advances in Neurology 80: 297-302, 1999

F15063, a potential antipsychotic with dopamine D2/D3 receptor antagonist, 5-HT1A receptor agonist and dopamine D4 receptor partial agonist properties: influence on neuronal firing and neurotransmitter release. European Journal of Pharmacology 607(1-3): 74-83, 2009

Effects of chronic, systemic treatment with the dopamine receptor agonist R-apomorphine in partially lesioned rat model of Parkinson's disease: an electrophysiological study of substantia nigra dopamine neurons. Chinese Journal of Physiology 54(2): 96-104, 2011

Effect of the dopamine receptor agonist apomorphine on sensory input. Naunyn-Schmiedeberg's Archives of Pharmacology 338(5): 489-496, 1988

The effect of methyltestosterone on the growth hormone response to the dopamine receptor agonist, apomorphine. Progress in Neuro-Psychopharmacology & Biological Psychiatry 15(2): 263-268, 1991

Effect of apomorphine, a dopamine receptor agonist, on penile tumescence in normal subjects. Progress in Neuro-Psychopharmacology & Biological Psychiatry 8(4-6): 695-699, 1984

A simple method for the study of yawning in man induced by the dopamine receptor agonist, apomorphine. Progress in Neuro-Psychopharmacology & Biological Psychiatry 11(2-3): 223-228, 1987

The morphogenesis of stereotyped behavior induced by the dopamine receptor agonist apomorphine in the laboratory rat. Neuroscience 14(3): 783-798, 1985

Antioxidant activity of iron chelating agents on iron loaded hepatocyte cultures study of their free radical scavenging properties. Clement, B And A Guillouzo (Ed ) Colloque Inserm (Institut National De La Sante Et De La Recherche Medicale), Vol 216 Aspects Cellulaires Et Moleculaires De La Cirrhose; (Inserm (National Institute Of Health And Medical Research) Colloquium, Vol 216 Cellular And Molecular Aspects Of Cirrhosis); International Conference on The Cellular And Molecular Bases Of Liver Cirrhosis, Rennes, France, July 3-5, 1991 Xv+380p Editions John Libbey Eurotext: Montrouge, France; London, England, Uk, 1992

Assessment of dopamine autoreceptor agonist properties of apomorphine, (+)-3-PPP and (-)-3-PPP by recording of yawning behaviour in rats. European Journal of Pharmacology 98(2): 307-310, 1984

Conditioning of pre- and post-synaptic behavioural responses to the dopamine receptor agonist apomorphine in rats. Psychopharmacology 91(1): 50-55, 1987

Similarities between a dopamine D3 receptor preferring agonist and apomorphine in MPTP-lesioned Parkinsonian monkeys. Society for Neuroscience Abstracts 23(1-2): 2432, 1997

Effect of dopamine receptor agonist apomorphine on scopolamine induced memory deficits in mice. Zhongguo Ying Yong Sheng Li Xue Za Zhi 30(3): 259-263, 2015

Application of the Bischier-Napieralski-Pschorr radiosynthesis of (R)-(-)-apomorphine, a non-selective D-1/D-2 dopamine receptor agonist. Journal of Labelled Compounds and Radiopharmaceuticals 49(6): 517-531, 2006

Behavioural effects in the rat of the putative dopamine D-3 receptor agonist 7-OH-DPAT: Comparison with quinpirole and apomorphine. Psychopharmacology 124(3): 231-240, 1996